Drug intelligence / Profile preview

ASC09F + oseltamivir

Development stage: Unknown
Lead developer: Ascletis Pharma
Modality: Small Molecules
Administration: Oral

Overview

ASC09F + oseltamivir is a combination antiviral therapy that consists of ASC09F (TMC-310911), a protease inhibitor, and oseltamivir (Tamiflu), a neuraminidase inhibitor. This combination has been investigated for the treatment of COVID-19. ASC09F appears to target the COVID-19 3C-like protease (3CLpro), while oseltamivir works by inhibiting the viral neuraminidase enzyme found on influenza viruses, preventing viral replication and infectivity.

Targets

Mpro (3C-like proteinase of SARS-CoV-2)Neuraminidase

Beyond the preview

Go deeper on ASC09F + oseltamivir.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ASC09F + oseltamivir.

Explore the full profile